<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980379</url>
  </required_header>
  <id_info>
    <org_study_id>SSGJ-304-NHL-I-02</org_study_id>
    <nct_id>NCT03980379</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Efficacy and Safety of the 304 Injection</brief_title>
  <official_title>A Study of Pharmacokinetics, Efficacy, and Safety of 304 Injection Compared With Rituximab in B Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic of the experimental drug 304
      injection compared with rituximab injection in patients with CD20 positive B-cell non-Hodgkin
      lymphoma who had previously achieved CR/CRu status but had not deteriorated or relapsed.
      While to assess the safety and efficacy of the experimental drug 304 injection compared with
      rituximab injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, parallel controlled, single-dose study to
      evaluate the pharmacokinetic, safety and efficacy of 304 injection compared with rituximab
      injection. To avoid the impact of tumor burden on pharmacokinetics, this study will be
      conducted in CD20 positive B-cell non-Hodgkin lymphoma patients who have achieved CR/CRu
      status and have not yet deteriorated or relapsed. All patients will be randomly averagely
      entered into the experimental group and the control group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC [0-t]</measure>
    <time_frame>For 85 days</time_frame>
    <description>To assess PK parameter of plasma 304 or rituximab: Area under the concentration-time curve from time zero to last time of quantifiable concentration (AUC [0-t])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC [0-∞]</measure>
    <time_frame>For 85 days</time_frame>
    <description>To assess PK parameter of plasma 304 or rituximab:
Area under the concentration-time curve from time zero extrapolated to infinity (AUC [0-∞])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>For 85 days</time_frame>
    <description>To assess PK parameter of plasma 304 or rituximab：Observed maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>For 85 days</time_frame>
    <description>To assess PK parameter of plasma 304 or rituximab：Time to Cmax (tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>For 85 days</time_frame>
    <description>To assess PK parameter of plasma 304 or rituximab：Elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT</measure>
    <time_frame>For 85 days</time_frame>
    <description>To assess PK parameter of plasma 304 or rituximab：Mean residence time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz</measure>
    <time_frame>For 85 days</time_frame>
    <description>To assess PK parameter of plasma 304 or rituximab：Apparent volume of distribution(Vz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLz</measure>
    <time_frame>For 85 days</time_frame>
    <description>To assess PK parameter of plasma 304 or rituximab：apparent clearance (CLz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADA</measure>
    <time_frame>Up to 9 months</time_frame>
    <description>To evaluate the incidence of anti-304 and anti-rituximab antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>To evaluate the adverse events (incidence, severity, outcome, causality with the investigational drug, etc.).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>CD20 Positive B Cell NHL</condition>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>304 injection.WILL be administered single dose IV in the patients with CD20 positive B cell NHL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab will be administered single dose IV in the patients with CD20 positive B cell NHL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>304 injection</intervention_name>
    <description>Monoclonal antibodies, 100mg/10ml per injection</description>
    <arm_group_label>experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab injection</intervention_name>
    <description>100mg/10ml per injection ，manufactured by Roche</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological examination confirmed CD20-positive B-cell non-Hodgkin's lymphoma
             patients (according to WHO 2008 lymphoid tissue tumor type, and a corresponding
             medical history basis);

          -  Previous treatments with CR/CRu (see Appendix 1 for lymphoma efficacy criteria) and
             those with CD20-positive B-cell non-Hodgkin's lymphoma who have not yet worsened and
             relapsed believe that they can benefit from anti-CD20 monoclonal antibody therapy. The
             diagnosis of CRu requires complete raw data (using CT findings. The preferred enhanced
             CT examination)

          -  At the time of enrollment, the Eastern Oncology Cooperative Group (ECOG) had a
             physical status score of ≤1 (see Appendix 2 for the evaluation criteria for the ECOG
             physical status score) and the expected survival period was more than four months

          -  In the screening test, WBC≥3×109/L, HGB≥80g/L, ANC≥1.5×109/L, PLT≥75×109/L, left
             ventricular ejection fraction (LVEF) ) ≥ 50%

          -  Female patients of childbearing age were negative for the blood pregnancy test during
             the screening period. Patients of childbearing age are willing to contraception after
             signing the informed consent form until 6 months after the end of the study treatment,
             including but not limited to: hormonal contraception, or physical contraception, or
             abstinence

          -  Be able to understand and comply with clinical trial protocol requirements and
             voluntarily sign written informed consent

        Exclusion Criteria:

          -  In the past 5 years, there have been other medical history of malignant tumors (except
             for local malignant tumors that have been cured, such as cutaneous basal cell
             carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma
             in situ or breast carcinoma in situ)

          -  Those who have used chemotherapy drugs within 4 weeks before enrollment

          -  The clinical half-life of more than 5 drugs after taking other clinical trials in
             three months or other clinical trials (whichever is longer)

          -  The last time you used rituximab or other anti-CD20 mAbs for no more than 4 months

          -  In the screening test, the liver and kidney function tests have any of the following
             abnormalities: total bilirubin &gt; 1.5 times the upper limit of normal, ALT &gt; 2.5 times
             the upper limit of normal, AST &gt; 2.5 times the upper limit of normal, ALP &gt; 2.5 times
             the upper limit of normal, Blood Cr&gt;1.5 times the upper limit of normal value

          -  Hyperthyroidism

          -  He was transfused within 2 weeks before enrollment, or hematopoietic cytokine therapy,
             such as granulocyte colony-stimulating factor (G-CSF), thrombopoietin, erythropoietin,
             etc.

          -  Those who were vaccinated or planned to vaccinate (attenuate) live virus vaccine
             within 4 weeks prior to enrollment;

          -  Oversized surgery (not including diagnostic surgery) in the past 8 weeks;

          -  Have evidence or history of central nervous system involvement or cranial neuropathy;

          -  Treponema pallidum antibody positive, or HIV antibody positive, or HCV antibody
             positive;

          -  HBV examination showed one of the following results: a, HBsAg positive; b, although
             HBsAg negative, but anti-HBc positive and peripheral blood HBV DNA titer can be
             measured;

          -  Have had herpes zoster and have sequelae or latent infections;

          -  Patients with a history of severe heart disease, including but not limited to: New
             York Heart Association NYHA class II-IV heart failure (see Appendix 3 for NYHA heart
             failure grading), uncontrolled angina or arrhythmia, heart conduction above II
             Blocking, myocardial infarction occurred within 6 months

          -  Serious illnesses that have been or are currently suffering from any other organ or
             system (including but not limited to: severely active infections, uncontrolled
             diabetes, uncontrolled hypertension/hypotension, cerebrovascular disease, gastric
             ulcers, respiratory diseases, activities) Sexual autoimmune diseases, etc.; and any
             other medical history that the subject judges to be unsuitable for participating in
             the trial;

          -  Pregnant or lactating female subjects, or those who are unwilling to contraception
             during the trial

          -  Severe allergies, or any component known to be rituximab or other anti-CD20 mAbs or
             allergic to murine proteins;

          -  Subjects had a history of drug abuse or a history of smoking and drinking during the
             first 6 months of enrollment;

          -  The investigator judged that the patient was not suitable for entering any other
             circumstances of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gang Tong</last_name>
    <phone>+86- 21- 84892211</phone>
    <email>tonggang@3sbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The 307 Hospital of People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hang Su</last_name>
      <phone>13701396736</phone>
      <email>suhang307@126.com</email>
    </contact>
    <investigator>
      <last_name>hang Su</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dong Yan</last_name>
      <phone>13621308215</phone>
      <email>yd15yt88@163.com</email>
    </contact>
    <investigator>
      <last_name>dong Yan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510600</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huiqiang huang</last_name>
      <phone>020-87343535</phone>
      <email>huanghq@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>huiqiang huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lihong Liu</last_name>
      <phone>13831177920;</phone>
      <email>13831177920@163.com</email>
    </contact>
    <investigator>
      <last_name>Lihong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Heibei</state>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>aimin Zang</last_name>
      <phone>03125983056</phone>
      <email>hdfygcp@163.com</email>
    </contact>
    <investigator>
      <last_name>aimin Zang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Central Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shanyong Yi</last_name>
      <phone>15516991321</phone>
      <email>yisy2001@126.com</email>
    </contact>
    <investigator>
      <last_name>shanyong Yi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospita of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mingzhi Zhang</last_name>
      <phone>13838565629</phone>
      <email>mingzhi_zhang@126.com</email>
    </contact>
    <investigator>
      <last_name>mingzhi Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weihai Municipal Hospital</name>
      <address>
        <city>Weihai</city>
        <state>Shandong</state>
        <zip>264200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>xiuzhi Deng</last_name>
      <phone>18660377358</phone>
      <email>18660377358@126.com</email>
    </contact>
    <investigator>
      <last_name>xiuzhi Deng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp;Hospital</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjing</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanfang Li</last_name>
      <phone>18622221613</phone>
      <email>Lilanfangmeng@163.com</email>
    </contact>
    <investigator>
      <last_name>Lanfang Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Zhejiang</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhixiang Zhuang</last_name>
      <phone>13951106391</phone>
      <email>13951106391@139.com</email>
    </contact>
    <investigator>
      <last_name>zhixiang Zhuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

